이 누리집은 대한민국 공식 전자정부 누리집입니다.
Biz News Korea(Eng)
Il-yang Pharma’s Supect proves to be effective in delaying Parkinson’s disease
- Collected
- 2017.11.08
- Distributed
- 2017.11.09
- Source
- Go Direct
Il-yang Pharmaceutical`s Supect
According to Il-yang Pharmaceutical, the company has proved that its drug called Supect, or radotinib, inhibits the progress of Parkinson’s disease during the tests on cells and animals jointly conducted by Johns Hopkins research team over the last two years. A series of studies showed the drug, which the Korean drug maker has developed to cure chronic myelogenous leukemia, has successfully lowered the cohesion of protein alpha-synuclein, a constituent of Lewy bodies or abnormal protein aggregates that can cause Parkinson’s disease, the company said.
Il-yang Pharmaceutical said it will present the results of its pre-clinical research at a Society for Neuroscience meeting in the United States that will be held from Nov. 11 to 15.
An unnamed official from Il-yang Pharmaceutical said the latest research results have raised expectations that Supect could be used in treating Parkinson’s disease.
Parkinson’s is a degenerative neuronal disease mainly resulting from dopamine deficiency. Symptoms of the disease include tremor or shaking in the hand or arm and difficulty in walking and balancing, but the exact cause has not been identified.
By Kim Hye-soon and Lee Eun-joo
[ⓒ Pulse by Maeil Business News Korea & mk.co.kr, All rights reserved]